Add a header block to begin generating the table of contents. This block will automatically update. Alternatively manually add items using the + button below. Once you have added at least one item this message will disappear.
Chengdu Shengnuo Biotechnology Co., Ltd.
Stock code: 688117
Stock abbreviation: Shengnuo Biotech
Company Name: Chengdu Shengnuo Biotechnology Co., Ltd.
Company English name: Cheng Du Sheng Nuo Biotec Co.,Ltd.
Brief company history:
Chengdu Shengnuo Biotechnology Co., Ltd. was established in July 2001 and is located in Dayi County, Chengdu City. It has a registered capital of 60 million yuan and its wholly-owned subsidiary is Chengdu Sennuo Biopharmaceutical Co., Ltd. From the initial registered capital of 1 million, the company’s total assets now reach 250 million, achieving good and rapid development. Owning the “Chengdu Peptide Drug Engineering Technology Research Center”, Sirnaomics has passed the US FDA certification and has now become a peptide drug industrial park specializing in peptide drug and product development, technology transfer, technical services, large-scale production and export.
The company participated in the National Eleventh Five-Year Plan major new drug creation project “Research on Key Technologies for Peptide Chemical Modification and Industrial Scale Preparation”, and the National Science and Technology Small and Medium Enterprises Technology Innovation Fund’s free funding project “New Anti-Heart Failure Drug Nesiritide” has entered the In the clinical research stage, in 2010, it received special funding support for emerging industries from the Sichuan Provincial Economic Commission to conduct research on the transformation of industrialization results of peptide drugs.
The above-mentioned projects have completed the project construction content. It has key technologies for the large-scale production of more than 50 peptide drugs and products that have been marketed at home and abroad, and the single batch output can reach kg level; it has large-scale production technology of thiocyclic peptides, large-scale production of carbocyclic peptides, complex peptide technology, and polypeptide technology. Rapid synthesis technology and other international technologies.
The founder of the company, Mr. Wen Yongjun, is the originator of Hainan Zhonghe’s thymopentin (Heri), a domestically marketed peptide drug, and thymosin α1, which has a single product sales revenue of over 500 million, as well as the leader of the stable peptide drug R&D and production team. The company pays attention to the integration of learning and research, and has formed close industry-university-research strategic partnerships with scientific research institutions such as Sichuan University, Lanzhou University, Jilin University, Academy of Military Sciences, Institute of Organic Chemistry, Chinese Academy of Sciences, and Provincial Institute for Drug Control; it has provided services to Chengdu Diao, Zhejiang Hisun, and Harbin Pharmaceutical. , Hainan Zhonghe, etc. have successfully realized the industrial transformation of multiple new class I peptide drugs.
The company cooperates closely with the foreign pharmaceutical peptide industry. It cooperates with a peptide manufacturer in India and provides training and production guidance to employees in the Indian factory. The technologies used are all the company’s own technologies; it maintains contact with international polypeptide technology research units and Exchange, study the structure and function of biotech drugs from multiple angles and in-depth, and lay a solid foundation for further application in practical applications and accumulation of scientific data.
Registered address: Section 1, Industrial Avenue, Jinyuan Town, Dayi County, Chengdu City, Sichuan Province (within the Industrial Concentrated Development Zone)
Office address: Section 1, Industrial Avenue, Jinyuan Town, Dayi County, Chengdu City, Sichuan Province (within the Industrial Concentrated Development Zone)
Region: Sichuan Province
Industry: Medicine
Company website: www.biofda.com
Email: roleagh@gmail.com
Main business scope: Research, development, and sales of biopharmaceutical intermediates (excluding drugs, precursors, dangerous chemicals, and blood products), as well as related technology transfer and technical consultation. (Projects that require approval according to law can only carry out business activities after approval by relevant departments).
Company products: 688117 Levosimendan Injection 688117 Enfuvirtide for Injection 688117 Carbetocin Injection 688117 Octreotide Acetate Injection 688117 Atosiban Acetate Injection
Other Polypeptide APIs Products
peptide synthesis companies
| Polypeptide APIs Products |
| US-DMF LIST |
| Beauty peptides |
| Chinese cGMP APIs |
| Mexico Registered APIs |
| Research Peptide APIs for Regulatory Market |
| Polypeptide Preparation |
| Kaijie bio medicine Peptide APIs |